|
1
|
Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling.
|
Nat Biotechnol
|
2009
|
13.16
|
|
2
|
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.
|
Sci Transl Med
|
2013
|
7.99
|
|
3
|
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.
|
Blood
|
2011
|
7.49
|
|
4
|
Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs.
|
Nature
|
2009
|
7.04
|
|
5
|
Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.
|
Nat Med
|
2003
|
6.81
|
|
6
|
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.
|
Sci Transl Med
|
2014
|
5.60
|
|
7
|
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.
|
Nat Biotechnol
|
2002
|
5.49
|
|
8
|
Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial.
|
Mol Ther
|
2010
|
4.54
|
|
9
|
Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.
|
Clin Cancer Res
|
2007
|
4.42
|
|
10
|
Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells.
|
Nat Biotechnol
|
2012
|
3.28
|
|
11
|
Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.
|
J Immunother
|
2009
|
3.11
|
|
12
|
T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection.
|
Nat Med
|
2007
|
3.07
|
|
13
|
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.
|
Blood
|
2012
|
2.86
|
|
14
|
Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-Myc expression for efficient human iPSC induction and differentiation.
|
Proc Natl Acad Sci U S A
|
2009
|
2.86
|
|
15
|
CARs on track in the clinic.
|
Mol Ther
|
2011
|
2.86
|
|
16
|
Conserved vertebrate mir-451 provides a platform for Dicer-independent, Ago2-mediated microRNA biogenesis.
|
Proc Natl Acad Sci U S A
|
2010
|
2.67
|
|
17
|
Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication.
|
Mol Ther
|
2009
|
2.52
|
|
18
|
Genomic safe harbors permit high β-globin transgene expression in thalassemia induced pluripotent stem cells.
|
Nat Biotechnol
|
2010
|
2.43
|
|
19
|
A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity.
|
J Immunol
|
2009
|
2.43
|
|
20
|
miR-371-3 expression predicts neural differentiation propensity in human pluripotent stem cells.
|
Cell Stem Cell
|
2011
|
2.33
|
|
21
|
Occurrence of leukaemia following gene therapy of X-linked SCID.
|
Nat Rev Cancer
|
2003
|
2.08
|
|
22
|
Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase.
|
Nat Med
|
2009
|
1.98
|
|
23
|
T-cell therapy at the threshold.
|
Nat Biotechnol
|
2012
|
1.91
|
|
24
|
A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer.
|
Blood
|
2002
|
1.89
|
|
25
|
Human ESC-derived hemogenic endothelial cells undergo distinct waves of endothelial to hematopoietic transition.
|
Blood
|
2012
|
1.87
|
|
26
|
Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes.
|
Nat Biotechnol
|
2003
|
1.87
|
|
27
|
PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses.
|
Sci Transl Med
|
2013
|
1.76
|
|
28
|
A genetic strategy for single and combinatorial analysis of miRNA function in mammalian hematopoietic stem cells.
|
Stem Cells
|
2010
|
1.73
|
|
29
|
Targeted elimination of prostate cancer by genetically directed human T lymphocytes.
|
Cancer Res
|
2005
|
1.67
|
|
30
|
How do CARs work?: Early insights from recent clinical studies targeting CD19.
|
Oncoimmunology
|
2012
|
1.66
|
|
31
|
Multifactorial optimization of gammaretroviral gene transfer into human T lymphocytes for clinical application.
|
Hum Gene Ther
|
2007
|
1.62
|
|
32
|
Migration and differentiation of neural precursors derived from human embryonic stem cells in the rat brain.
|
Nat Biotechnol
|
2005
|
1.54
|
|
33
|
Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence.
|
J Clin Oncol
|
2012
|
1.50
|
|
34
|
In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy.
|
Cancer Res
|
2011
|
1.48
|
|
35
|
Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial.
|
Clin Cancer Res
|
2003
|
1.43
|
|
36
|
Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy.
|
Nat Biotechnol
|
2013
|
1.39
|
|
37
|
Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging.
|
J Nucl Med
|
2008
|
1.35
|
|
38
|
A method to sequence and quantify DNA integration for monitoring outcome in gene therapy.
|
Nucleic Acids Res
|
2011
|
1.33
|
|
39
|
Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene.
|
Blood
|
2002
|
1.29
|
|
40
|
IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice.
|
Blood
|
2010
|
1.29
|
|
41
|
American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells.
|
Mol Ther
|
2003
|
1.29
|
|
42
|
The ABCs of artificial antigen presentation.
|
Nat Biotechnol
|
2004
|
1.29
|
|
43
|
A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference.
|
Nat Biotechnol
|
2005
|
1.28
|
|
44
|
CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems.
|
Vaccine
|
2004
|
1.25
|
|
45
|
Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients.
|
Clin Cancer Res
|
2012
|
1.25
|
|
46
|
Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors.
|
Nat Biotechnol
|
2008
|
1.24
|
|
47
|
Intercellular transfer of P-glycoprotein mediates acquired multidrug resistance in tumor cells.
|
Proc Natl Acad Sci U S A
|
2005
|
1.24
|
|
48
|
CAR therapy: the CD19 paradigm.
|
J Clin Invest
|
2015
|
1.20
|
|
49
|
CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia.
|
PLoS One
|
2013
|
1.19
|
|
50
|
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.
|
J Clin Invest
|
2016
|
1.18
|
|
51
|
Harnessing endogenous miR-181a to segregate transgenic antigen receptor expression in developing versus post-thymic T cells in murine hematopoietic chimeras.
|
J Clin Invest
|
2008
|
1.16
|
|
52
|
Stem cell-derived erythroid cells mediate long-term systemic protein delivery.
|
Nat Biotechnol
|
2006
|
1.16
|
|
53
|
Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma.
|
Clin Cancer Res
|
2013
|
1.16
|
|
54
|
In vivo imaging and quantitation of adoptively transferred human antigen-specific T cells transduced to express a human norepinephrine transporter gene.
|
Cancer Res
|
2007
|
1.15
|
|
55
|
The genetic engineering of hematopoietic stem cells: the rise of lentiviral vectors, the conundrum of the ltr, and the promise of lineage-restricted vectors.
|
Mol Ther
|
2007
|
1.13
|
|
56
|
Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients.
|
Cancer Immunol Immunother
|
2011
|
1.12
|
|
57
|
Multiple stages of malignant transformation of human endothelial cells modelled by co-expression of telomerase reverse transcriptase, SV40 T antigen and oncogenic N-ras.
|
Oncogene
|
2002
|
1.12
|
|
58
|
Hematopoietic stem cell engineering at a crossroads.
|
Blood
|
2011
|
1.10
|
|
59
|
Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination.
|
Int J Cancer
|
2005
|
1.07
|
|
60
|
The potential of stem cells as an in vitro source of red blood cells for transfusion.
|
Cell Stem Cell
|
2012
|
1.06
|
|
61
|
Limited proliferation and telomere dysfunction following telomerase inhibition in immortal murine fibroblasts.
|
Cancer Res
|
2002
|
1.03
|
|
62
|
Busulfan pharmacokinetics, toxicity, and low-dose conditioning for autologous transplantation of genetically modified hematopoietic stem cells in the rhesus macaque model.
|
Exp Hematol
|
2006
|
1.03
|
|
63
|
Gene therapy through autologous transplantation of gene-modified hematopoietic stem cells.
|
Biol Blood Marrow Transplant
|
2012
|
1.02
|
|
64
|
Concurrent visualization of trafficking, expansion, and activation of T lymphocytes and T-cell precursors in vivo.
|
Blood
|
2010
|
1.01
|
|
65
|
Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.
|
Prostate
|
2009
|
1.00
|
|
66
|
A new pyrimidine-specific reporter gene: a mutated human deoxycytidine kinase suitable for PET during treatment with acycloguanosine-based cytotoxic drugs.
|
J Nucl Med
|
2010
|
1.00
|
|
67
|
Generation of transgene-free human induced pluripotent stem cells with an excisable single polycistronic vector.
|
Nat Protoc
|
2011
|
0.99
|
|
68
|
Safe mobilization of CD34+ cells in adults with β-thalassemia and validation of effective globin gene transfer for clinical investigation.
|
Blood
|
2014
|
0.97
|
|
69
|
High-throughput sequencing reveals principles of adeno-associated virus serotype 2 integration.
|
J Virol
|
2013
|
0.97
|
|
70
|
Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele.
|
Blood
|
2003
|
0.97
|
|
71
|
A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy.
|
J Immunol
|
2009
|
0.97
|
|
72
|
Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity.
|
J Clin Invest
|
2013
|
0.96
|
|
73
|
Ligand binding to inhibitory killer cell Ig-like receptors induce colocalization with Src homology domain 2-containing protein tyrosine phosphatase 1 and interruption of ongoing activation signals.
|
J Immunol
|
2004
|
0.95
|
|
74
|
Retroviral transduction of murine primary T lymphocytes.
|
Methods Mol Biol
|
2009
|
0.94
|
|
75
|
Locus control region elements HS1 and HS4 enhance the therapeutic efficacy of globin gene transfer in beta-thalassemic mice.
|
Blood
|
2007
|
0.94
|
|
76
|
[131I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicity.
|
Eur J Nucl Med Mol Imaging
|
2006
|
0.94
|
|
77
|
Benefits of utilizing gene-modified iPSCs for clinical applications.
|
Cell Stem Cell
|
2010
|
0.92
|
|
78
|
Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells.
|
Cancer Res
|
2005
|
0.90
|
|
79
|
Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.
|
Cancer Immunol Immunother
|
2011
|
0.90
|
|
80
|
An in vivo platform for tumor biomarker assessment.
|
PLoS One
|
2011
|
0.89
|
|
81
|
Current status of globin gene therapy for the treatment of beta-thalassaemia.
|
Br J Haematol
|
2008
|
0.88
|
|
82
|
Adenoviral transduction of human acid sphingomyelinase into neo-angiogenic endothelium radiosensitizes tumor cure.
|
PLoS One
|
2013
|
0.87
|
|
83
|
Erythroid-specific human factor IX delivery from in vivo selected hematopoietic stem cells following nonmyeloablative conditioning in hemophilia B mice.
|
Mol Ther
|
2008
|
0.87
|
|
84
|
Animal models and molecular imaging tools to investigate lymph node metastases.
|
J Mol Med (Berl)
|
2011
|
0.87
|
|
85
|
Large-scale clinical-grade retroviral vector production in a fixed-bed bioreactor.
|
J Immunother
|
2015
|
0.85
|
|
86
|
Fetal gene therapy of alpha-thalassemia in a mouse model.
|
Proc Natl Acad Sci U S A
|
2007
|
0.85
|
|
87
|
Cutting Edge: CD28 controls dominant regulatory T cell activity during active immunization.
|
J Immunol
|
2006
|
0.84
|
|
88
|
Langerhans cells derived from genetically modified human CD34+ hemopoietic progenitors are more potent than peptide-pulsed Langerhans cells for inducing antigen-specific CD8+ cytolytic T lymphocyte responses.
|
J Immunol
|
2005
|
0.83
|
|
89
|
Novel approaches to enhance the specificity and safety of engineered T cells.
|
Cancer J
|
2014
|
0.83
|
|
90
|
Therapeutic globin gene delivery using lentiviral vectors.
|
Curr Opin Mol Ther
|
2002
|
0.83
|
|
91
|
Recovery and Biodistribution of Ex Vivo Expanded Human Erythroblasts Injected into NOD/SCID/IL2Rγ mice.
|
Stem Cells Int
|
2011
|
0.82
|
|
92
|
Derivation of genetically modified human pluripotent stem cells with integrated transgenes at unique mapped genomic sites.
|
Nat Protoc
|
2011
|
0.81
|
|
93
|
Functional assessment of the engraftment potential of gammaretrovirus-modified CD34+ cells, using a short serum-free transduction protocol.
|
Hum Gene Ther
|
2006
|
0.81
|
|
94
|
Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer.
|
Neoplasia
|
2013
|
0.81
|
|
95
|
Frequency of missense mutations in the coding region of a eukaryotic gene transferred by retroviral vectors.
|
J Virol
|
2002
|
0.80
|
|
96
|
Transient in vivo beta-globin production after lentiviral gene transfer to hematopoietic stem cells in the nonhuman primate.
|
Hum Gene Ther
|
2009
|
0.80
|
|
97
|
Novel strategies for cancer therapy: the potential of genetically modified T lymphocytes.
|
Curr Hematol Rep
|
2004
|
0.79
|
|
98
|
Fulminant experimental autoimmune encephalo-myelitis induced by retrovirally mediated TCR gene transfer.
|
Eur J Immunol
|
2005
|
0.79
|
|
99
|
Development of a new reporter gene system--dsRed/xanthine phosphoribosyltransferase-xanthine for molecular imaging of processes behind the intact blood-brain barrier.
|
Mol Imaging
|
2003
|
0.79
|
|
100
|
T cell activation upon exposure to patient-derived tumor tissue: a functional assay to select patients for adoptive T cell therapy.
|
J Immunol Methods
|
2010
|
0.79
|
|
101
|
Gene therapy for homozygous beta-thalassemia. Is it a reality?
|
Hemoglobin
|
2009
|
0.78
|
|
102
|
Production of clinical-grade plasmid DNA for human Phase I clinical trials and large animal clinical studies.
|
Vaccine
|
2007
|
0.78
|
|
103
|
PLZF confers effector functions to donor T cells that preserve graft-versus-tumor effects while attenuating GVHD.
|
Cancer Res
|
2013
|
0.78
|
|
104
|
Tolerance induction by allogeneic hematopoietic stem cells.
|
Cell Stem Cell
|
2011
|
0.78
|
|
105
|
Eliminating cells gone astray.
|
N Engl J Med
|
2011
|
0.78
|
|
106
|
CD19 target-engineered T-cells accumulate at tumor lesions in human B-cell lymphoma xenograft mouse models.
|
Biochem Biophys Res Commun
|
2013
|
0.77
|
|
107
|
Highly divergent integration profile of adeno-associated virus serotype 5 revealed by high-throughput sequencing.
|
J Virol
|
2013
|
0.77
|
|
108
|
Adeno-associated virus type 2 preferentially integrates single genome copies with defined breakpoints.
|
Virol J
|
2014
|
0.77
|
|
109
|
Towards the genetic treatment of beta-thalassemia: new disease models, new vectors, new cells.
|
Haematologica
|
2008
|
0.77
|
|
110
|
The need for genetically engineering therapeutic pluripotent stem cells.
|
Mol Ther
|
2010
|
0.77
|
|
111
|
Reconstructing blood from induced pluripotent stem cells.
|
F1000 Med Rep
|
2010
|
0.77
|
|
112
|
Langerhans-type dendritic cells genetically modified to express full-length antigen optimally stimulate CTLs in a CD4-dependent manner.
|
J Immunol
|
2006
|
0.76
|
|
113
|
A New Induction to the Gene and Cell Therapy Hall Of Fame: Genome Editing.
|
Mol Ther
|
2016
|
0.75
|
|
114
|
Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia.
|
J Clin Invest
|
2016
|
0.75
|
|
115
|
A "vector drain" in US gene therapy development?
|
Mol Ther
|
2008
|
0.75
|
|
116
|
Somatic cell engineering and the immunotherapy of leukemias and lymphomas.
|
Adv Pharmacol
|
2004
|
0.75
|
|
117
|
Scalable expansion of potent genetically modified human langerhans cells in a closed system for clinical applications.
|
J Immunother
|
2007
|
0.75
|
|
118
|
The meaning of translation.
|
Cancer Invest
|
2006
|
0.75
|
|
119
|
Genetic strategies for the treatment of sickle cell anaemia.
|
Br J Haematol
|
2011
|
0.75
|